Cutia Therapeutics 02487
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$15.24
- Day Range
- HK$15.28–16.56
- 52-Week Range
- HK$5.57–24.00
- Bid/Ask
- HK$16.10 / HK$16.20
- Market Cap
- HK$4.92 Bil
- Volume/Avg
- 446,400 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 2.52
- Price/Sales
- 22.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 298
- Website
- https://www.cutiatx.com
Comparables
Valuation
|
Metric
|
02487
|
02509
|
6617
|
|---|---|---|---|
Price/Earnings (Normalized) | 2.52 | — | — |
Price/Book Value | 5.38 | 35.24 | 4.50 |
Price/Sales | 22.88 | 108.12 | 419.23 |
Price/Cash Flow | — | — | — |
Price/Earnings
02487
02509
6617
Financial Strength
|
Metric
|
02487
|
02509
|
6617
|
|---|---|---|---|
Quick Ratio | 4.64 | 1.70 | 10.19 |
Current Ratio | 5.09 | 1.86 | 10.28 |
Interest Coverage | −70.28 | −18.42 | −39.00 |
Quick Ratio
02487
02509
6617
Profitability
|
Metric
|
02487
|
02509
|
6617
|
|---|---|---|---|
Return on Assets (Normalized) | −25.48% | −47.40% | −4.63% |
Return on Equity (Normalized) | −38.73% | −341.08% | −5.29% |
Return on Invested Capital (Normalized) | −27.32% | −56.34% | −6.89% |
Return on Assets
02487
02509
6617
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rdqplcxvf | Spkd | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cccqkkpx | Rlrvy | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jtqgrwdw | Bggggd | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fwbktcygf | Hqvlp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Jtsgbdxz | Svx | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Synyqvxf | Vst | $28.1 Bil | |||
| Moderna Inc
MRNA
| Kfjfczl | Sjh | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Pmbbbhcf | Cyqps | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mtwjzrjy | Jslhkv | $13.4 Bil | |||
| Incyte Corp
INCY
| Wpfskgy | Lfsnz | $12.7 Bil |
United States